10/29/2026
An important update for patients interested in peptide therapy.
HHS has issued an interim enforcement-discretion policy covering certain 503A compounding preparations of BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.
For our patients, this may open a pathway for our pharmacy to provide certain compounded peptides pursuant to a valid prescription when the medication meets the policy’s requirements. We’re reviewing those requirements and expect to offer eligible compounds in the near future as we receive additional clarification. We’re excited about these next steps.
Compounded medications are not FDA-approved. The FDA does not review them for safety, efficacy, or quality before they are marketed. These preparations require a prescription from a prescriber and must be compounded by a 503A compounding pharmacy in accordance with applicable requirements.
If you have questions or are interested, please reach out to us.
